Kiadis Pharma (KIADF) Stock Price, News & Analysis

Company Overview

Kiadis Pharma N.V. is a clinical‐stage biopharmaceutical company headquartered in Amsterdam, the Netherlands, with additional offices in the United States and Europe. The company specializes in developing next‐generation immunotherapies designed to improve outcomes for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Its platform leverages donor-derived immune effector cells, including T‐cell receptor (ATIR) products and natural killer (NK) cell therapies, to reduce the incidence of relapse, infection and graft‐versus‐host disease.

The company’s lead investigational product, ATIR101, is an adoptive T‐cell therapy engineered to provide pathogen protection while minimizing the risk of graft‐versus‐host disease following HSCT. In parallel, Kiadis Pharma is advancing multiple NK cell candidates, including K-NK002 and K-NK003, which are being studied for their ability to target residual malignant cells in acute myeloid leukemia and other hematologic malignancies. These programs have generated encouraging safety and efficacy data in Phase I/II trials conducted in Europe and North America.

Founded in 1998 as a spin‐out from Radboud University Medical Center, Kiadis Pharma has built a global clinical trial network and established GMP‐compliant manufacturing facilities in the Netherlands and the U.S. The company collaborates with leading academic institutions, transplant centers and industry partners to accelerate development timelines and broaden patient access. Its research and development efforts are supported by a multidisciplinary team of experts in cell therapy, clinical hematology and regulatory affairs.

Under the leadership of CEO Dr. Daniel More, Kiadis Pharma is focused on achieving key regulatory milestones and expanding its pipeline toward potential market authorization. The management team, comprising seasoned professionals in biotechnology and oncology, continues to explore novel cell‐engineering approaches to address unmet needs in transplantation medicine. Kiadis Pharma trades on the OTC Markets under the symbol KIADF.

Key Stats

• Today's Range: $6.41 to $6.41
• 50-Day Range: $6.41 to $6.41
• 52-Week Range: $1.72 to $6.55
• Volume: N/A
• Average Volume: 1,800 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

KIADF Stock Analysis - Frequently Asked Questions

How have KIADF shares performed this year?

Kiadis Pharma's stock was trading at $6.41 on January 1st, 2025. Since then, KIADF stock has increased by 0.0% and is now trading at $6.41.

How do I buy shares of Kiadis Pharma?

Shares of KIADF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:KIADF
• CIK: N/A
• Web: www.kiadis.com
• Phone: 31 20 240 5250
• Fax: N/A
• Employees: 103
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A